FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 348:177-178 January 9, 2003 Number 2 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: Mutations in the YMDD (tyrosine, methionine, aspartate, aspartate) motif of the DNA polymerase resulting in phenotypic hepatitis B virus (HBV) resistance to lamivudine monotherapy have been observed after two years in 50 percent of patients coinfected with the human immunodeficiency virus (HIV).¹ Adefovir dipivoxil has been shown to be effective for lamivudine-resistant HBV infection in HIV-coinfected patients.² Tenofovir disoproxil fumarate, a nucleotide reverse-transcriptase inhibitor, is active against HIV and has in vitro activity against wild-type and lamivudine-resistant HBV.^3,4

We examined the efficacy and safety of tenofovir disoproxil fumarate, at a dose of 300 mg given once daily, . . . [Full Text of this Article]

This article has been cited by other articles:

• Menne, S., Butler, S. D., George, A. L., Tochkov, I. A., Zhu, Y., Xiong, S., Gerin, J. L., Cote, P. J., Tennant, B. C. (2008). Antiviral Effects of Lamivudine, Emtricitabine, Adefovir Dipivoxil, and Tenofovir Disoproxil Fumarate Administered Orally Alone and in Combination to Woodchucks with Chronic Woodchuck Hepatitis Virus Infection. Antimicrob. Agents Chemother. 52: 3617-3632 [Abstract] [Full Text]  
• Dusheiko, G, Antonakopoulos, N (2008). Current treatment of hepatitis B. Gut 57: 105-124 [Full Text]  
• Schildgen, O., Sirma, H., Funk, A., Olotu, C., Wend, U. C., Hartmann, H., Helm, M., Rockstroh, J. K., Willems, W. R., Will, H., Gerlich, W. H. (2006). Variant of hepatitis B virus with primary resistance to adefovir.. NEJM 354: 1807-1812 [Abstract] [Full Text]  
• Stephan, C., Berger, A., Carlebach, A., Lutz, T., Bickel, M., Klauke, S., Staszewski, S., Stuermer, M. (2005). Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus. J Antimicrob Chemother 56: 1087-1093 [Abstract] [Full Text]  
• Menne, S., Cote, P. J., Korba, B. E., Butler, S. D., George, A. L., Tochkov, I. A., Delaney, W. E. IV, Xiong, S., Gerin, J. L., Tennant, B. C. (2005). Antiviral Effect of Oral Administration of Tenofovir Disoproxil Fumarate in Woodchucks with Chronic Woodchuck Hepatitis Virus Infection. Antimicrob. Agents Chemother. 49: 2720-2728 [Abstract] [Full Text]  
• Chang, J. J., Wightman, F., Bartholomeusz, A., Ayres, A., Kent, S. J., Sasadeusz, J., Lewin, S. R. (2005). Reduced Hepatitis B Virus (HBV)-Specific CD4+ T-Cell Responses in Human Immunodeficiency Virus Type 1-HBV-Coinfected Individuals Receiving HBV-Active Antiretroviral Therapy. J. Virol. 79: 3038-3051 [Abstract] [Full Text]